These are exciting times for discovering the biological scope and the mechanisms of action for DNA and RNA molecules, which have great impact in health and diseases, including cancer and neurodevelopmental disorders. Epigenetic mechanisms, such as

postranslational modifications of chromatin (DNA and histones), play pivotal roles in development, cell differentiation and cell identity. Inappropriate regulation of epigenetic mechanisms has been implicated in common human diseases. Moreover, there has been a recent explosion of activity in the fields of RNA epigenetics and non-coding RNAs, which have become integral parts of the field of gene expression.

The meeting will gather scientists using diverse approaches, such as molecular biology, cell biology genetics, epigenomics, and biochemistry. Researchers from pharmaceutical companies and clinicians working in different fields but sharing the same interests will also find the meeting an ideal opportunity to meet, discuss and summarize their work.  The meeting will provide great opportunities for senior and junior scientists to meet the leaders in the field from both academia and industry, hence forging exciting interdisciplinary interactions and creating potential new collaborations in the booming area of epigenetics and epigenomics and their clinical impacts.

The 2nd Meeting on Epigenetics & Epigenomics will gather some of the most prominent academic speakers in the field, coming from top universities around the world. They will highlight the most recent findings on the mechanisms and physiopathological roles of epigenetic modifications in the development of diseases, including cancer. In addition, industry leaders will present exciting advancements, with opportunities for companies to showcase promising new technologies and therapeutic approaches in the rapidly evolving field of epigenetics and epigenomics. This unique forum will foster collaboration among scientists, pharmaceutical companies, and physicians, providing a platform for innovative ideas and future breakthroughs.